Opioid-Induced Constipation Market

 Market Overview:

The 7 major opioid-induced constipation markets reached a value of US$ 817.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,166.9 Million by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.

The opioid-induced constipation market has been comprehensively analyzed in IMARC's new report titled "Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Opioid-induced constipation is a type of chronic constipation primarily caused by opioids, which activate enteric receptors and increase tonic non-propulsive contractions in the large and small intestines. This can slow down the movement of stool through the digestive system, leading to difficulty passing stool and infrequent bowel movements. The common symptoms associated with this ailment include abdominal tenderness, bloating, distention, or bulging in the abdomen, alternating episodes of constipation and diarrhea, dry and hard stools, nausea, vomiting, weight loss, difficulty defecating, fatigue, etc. The diagnosis is usually based on the evaluation of the patient's symptoms, along with a physical and rectal examination to visualize abdominal distension and stool impaction. The commonly utilized assessment tools for evaluating the severity of the condition are Bristol Stool Scale and Rome IV diagnostic criteria. In some cases, additional testing may be required to determine the underlying cause of the ailment. This may include colonoscopies to examine the digestive system as well as fecal occult blood testing to evaluate infections or other medical issues inducing constipation.

The escalating utilization of opioid medications for acute pain, such as after surgery or injury, and chronic pain, including that associated with cancer or certain other medical conditions, is primarily driving the opioid-induced constipation market. Moreover, the widespread adoption of effective drugs, such as mu-opioid receptor antagonists and chloride channel type-2 activators, which help enhance intestinal relaxation and stool movements to provide symptom relief, is also bolstering the market growth. In addition to this, the inflating application of several diagnostic tools, including Patient Assessment of Constipation Symptoms (PAC-SYM) and PAC-Quality of Life, (PAC-QOL) to measure abdominal and rectal symptoms, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to introduce injectable opioid antagonists in order to treat advanced illnesses among patients. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of the hybrid approach, which includes pharmacological therapy and lifestyle modifications, such as increasing dietary fiber, focusing on fluid intake, maintaining physical wellness, etc., for treating the ailment, is expected to drive the opioid-induced constipation market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the opioid-induced constipation market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for opioid-induced constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the opioid-induced constipation market in any manner.

Recent Developments:

• In December 2023, Salix Pharmaceuticals, the U.S. Pain Foundation (USPF), and the International Foundation for Gastrointestinal Disorders (IFFGD) launched a collaboration to establish December 5 as opioid-induced constipation awareness day. The awareness day is intended to raise awareness about an often-overlooked side effect of opioids. This day will benefit patients suffering from opioid-induced constipation by removing the stigma and silence around the ailment.

Key Highlights:

• Opioid-induced constipation impacts 40%-86% of patients taking opioids.
• Opioid-induced constipation affects between 8.9% and 81.0% of the global population.
• Up to 63% of cancer patients experience opioid-induced constipation.
• Opioid-induced constipation is estimated to occur in 15-90% of chronic noncancer pain patients.
• According to surveys, the prevalence of opioid-induced constipation increases with age.

Drugs:

Amitiza (lubiprostone) is a medication used in the management of opioid-induced constipation. It is a bicyclic fatty acid generated from prostaglandin E1 that works by activating ClC-2 chloride channels on the apical surface of gastrointestinal epithelial cells, resulting in chloride-rich fluid secretion. These secretions soften the stool, improve motility, and stimulate spontaneous bowel motions.

Axelopran (TD-1211) is a once-daily, oral peripherally active mu-opioid receptor antagonist being developed by Theravance Biopharma for the management of opioid-induced constipation and related gastrointestinal symptoms. This medication candidate has undergone long-term toxicological testing and is intended to restore intestinal function while preserving analgesia.

Lactobacillus gasseri by BioGaia is a probiotic strain that is designed to treat opioid-induced constipation. It helps in restoring a healthy balance of gut bacteria, which might be disrupted by prolonged opioid use.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the opioid-induced constipation market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the opioid-induced constipation market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current opioid-induced constipation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance   
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the opioid-induced constipation market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the opioid-induced constipation market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the opioid-induced constipation market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of opioid-induced constipation across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of opioid-induced constipation by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of opioid-induced constipation by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with opioid-induced constipation across the seven major markets?
• What is the size of the opioid-induced constipation patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of opioid-induced constipation?
• What will be the growth rate of patients across the seven major markets?
   

Opioid-Induced Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for opioid-induced constipation drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the opioid-induced constipation market?
• What are the key regulatory events related to the opioid-induced constipation market?
• What is the structure of clinical trial landscape by status related to the opioid-induced constipation market?
• What is the structure of clinical trial landscape by phase related to the opioid-induced constipation market?
• What is the structure of clinical trial landscape by route of administration related to the opioid-induced constipation market?